One of Dr. Abou-Gharbia's discoveries is the immunosuppressant, Rapamycin, one of Wyeth's flagship products for the treatment of transplantation rejection, without the renal toxicity observed in current cyclosporine therapy. Due to his group's findings, many safe and effective carbamates of Rapamycin were identified and advanced for development. These efforts resulted in an issuance of 25 U.S. patents, 23 of which were issued in 1996 alone, which is an unprecedented accomplishment in this industry.

In the area of CNS research, Dr. Abou-Ghrabia's research efforts led to the discovery of anti-psychotic agents, gevotroline and carvotroline, and anxiolytic agents, salospirone and adatanserin. He also discovered and developed Effexor, the first of a unique, new class of antidepressants, which is prescribed worldwide.

Dr. Abou-Gharbia's superior leadership and creative abilities have resulted in the most significant discoveries and advancements that have come from Wyeth during the last 20 years. As head of the Chemical and Screening Sciences of Wyeth Research, Dr. Abou-Gharbia has demonstrated the ability to stimulate innovation, encourage scientific excellence and rigor, to move research vigorously to completion, to invigorate colleagues and peers, and overcome all obstacles. His current responsibilities include direction of the research activities of over 500 scientists at several corporate research centers dedicated to the drug discovery process.

In addition to his sizeable responsibilities at Wyeth, Dr. Abou-Garbia is an adjunct professor at Temple University's School of Pharmacy.